Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.
|Articles|May 29, 2012
Insurers Forcing Patients to Pay More for Costly Specialty Drugs
Advertisement
prescription drugs
cancer
r
heumatoid arthritis
Thousands of patients in California and across the nation who take expensive every month for , and other ailments are facing sticker shock at the pharmacy.
Aetna
Until recently, most of these patients typically paid modest co-pays for the advanced drugs. But increasingly, Anthem Blue Cross, and other insurers are shifting more prescriptions to a new category requiring patients to shoulder a larger share of the drug's cost.
Read the full story:
Source: Los Angeles Times
Advertisement
Related to this article
Inconsistent definitions limit pathological response as a soft tissue sarcoma marker, according to a narrative review.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the One Big Beautiful Bill Act
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
Medicaid Obesity GLP-1 Coverage May Offset Some Diabetes-Labeled Use
4
FAQ: How Payers Can Close HIV Prevention and PrEP Access Gaps
5